PAQR3 inhibits DLBCL progression in a ferroptotic way by restraining low-density lipoprotein receptor (LDLR) expression, thereby increasing GSH level and promote the expression of GPX4 and SLC7A11. Here, PAQR3 is linked to diffuse large B-cell lymphoma.